GlassScriptPhysician profile
Claudia Bartolini
NPI 1497071096
$3,766.99
in general payments reported to CMS, 2019-2025
23 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $260 · 2021: $483 · 2022: $497 · 2023: $595 · 2024: $741 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $905.61 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Aerie Pharmaceuticals, INC. | $460.93 | 2019-2021 | |
| Allergan, INC. | $407.07 | 2019-2022 | |
| Alcon Vision LLC | $380.46 | 2022-2025 | Hydrus Microstent, Rocklatan, Precision7 |
| Glaukos Corporation | $359.90 | 2021-2025 | Idose, Idosetr |
| Rxsight INC | $288.49 | 2024-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Sun Pharmaceutical Industries INC. | $162.18 | 2019-2025 | Cequa |
| Ivantis, INC | $124.47 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $106.74 | 2019-2021 | |
| Ocular Therapeutix, INC. | $104.27 | 2023-2025 | Dextenza |
| Bausch & Lomb Americas INC. | $98.86 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Sight Sciences, INC. | $86.03 | 2019-2020 | |
| New World Medical,INC. | $53.52 | 2023 | |
| Oyster Point Pharma, INC. | $49.28 | 2022 | |
| Horizon Therapeutics Plc | $29.45 | 2022-2023 | Tepezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $24.02 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Amgen INC. | $23.07 | 2024 | Tepezza |
| Thea Pharma INC. | $20.79 | 2025 | Iyuzeh |
| Biotissue Holdings INC. | $20.20 | 2025 | |
| Omeros Corporation | $20.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.38 | 2023 | |
| Johnson & Johnson Surgical Vision, INC. | $13.66 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Bartolini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.